Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants

Ähnliche Einträge

• A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants
  von: Ana Liza Andresan Sun, et al.
  Veröffentlicht: (2024)
• First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects
  von: Tomoki Kojima, et al.
  Veröffentlicht: (2026)
• Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers
  von: Jumar Etkins, et al.
  Veröffentlicht: (2025)
• Correction to “Genotype‐Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers”
  Veröffentlicht: (2026)
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study
  von: Avner Sandhu, et al.
  Veröffentlicht: (2025)